Technical Analysis for BYSI - BeyondSpring, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 2.23 | 1.13% | 0.03 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Support | Bullish | 0.00% | |
50 DMA Support | Bullish | 0.00% | |
Stochastic Buy Signal | Bullish | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Crossed Above 200 DMA | Bullish | 1.13% | |
Crossed Above 50 DMA | Bullish | 1.13% | |
Narrow Range Bar | Range Contraction | 1.13% | |
Oversold Stochastic | Weakness | 1.13% | |
Fell Below 200 DMA | Bearish | 2.76% |
Alert | Time |
---|---|
Outside Day | about 21 hours ago |
Fell Below 200 DMA | about 21 hours ago |
Fell Below 50 DMA | about 21 hours ago |
Fell Below Previous Day's Low | about 21 hours ago |
Down 2 % | about 21 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 04/18/2024
BeyondSpring, Inc. Description
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatment Chemotherapy Antineoplastic Drugs Small Cell Lung Cancer Cancer Therapies Organic Chemistry NSCLC Protein Kinase Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Neutropenia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.0 |
52 Week Low | 0.7777 |
Average Volume | 23,418 |
200-Day Moving Average | 2.19 |
50-Day Moving Average | 2.21 |
20-Day Moving Average | 2.32 |
10-Day Moving Average | 2.22 |
Average True Range | 0.13 |
RSI (14) | 47.92 |
ADX | 28.09 |
+DI | 20.45 |
-DI | 14.74 |
Chandelier Exit (Long, 3 ATRs) | 2.13 |
Chandelier Exit (Short, 3 ATRs) | 2.55 |
Upper Bollinger Bands | 2.54 |
Lower Bollinger Band | 2.10 |
Percent B (%b) | 0.29 |
BandWidth | 18.62 |
MACD Line | -0.01 |
MACD Signal Line | 0.01 |
MACD Histogram | -0.0245 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.37 | ||||
Resistance 3 (R3) | 2.36 | 2.30 | 2.34 | ||
Resistance 2 (R2) | 2.30 | 2.27 | 2.31 | 2.33 | |
Resistance 1 (R1) | 2.27 | 2.25 | 2.29 | 2.28 | 2.33 |
Pivot Point | 2.21 | 2.21 | 2.22 | 2.22 | 2.21 |
Support 1 (S1) | 2.18 | 2.18 | 2.20 | 2.19 | 2.13 |
Support 2 (S2) | 2.12 | 2.16 | 2.13 | 2.13 | |
Support 3 (S3) | 2.09 | 2.12 | 2.12 | ||
Support 4 (S4) | 2.10 |